13450-77-6

Basic information

• Product Name: (4-CHLORO-BENZOYLAMINO)-ACETIC ACID
• Synonyms: OTAVA-BB BB7210742318;4-chlorobenzoylglycine;4-chlorohippuricacid;n-(4-chlorobenzoyl)-glycin;n-(4-chlorobenzoyl)glycine;n-(p-chlorobenzoyl)glycine;p-chlorobenzoylglycine;p-chloro-hippuricaci
• CAS NO: 13450-77-6
• Molecular Formula: C₉H₈ClNO₃
• Molecular Weight: 213.62
• Mol File: 13450-77-6.mol
• Article Data: 24

Chemical Properties

• Melting Point: 144-146°
• Boiling Point: 457.2 °C at 760 mmHg
• Flash Point: 230.3 °C
• Appearance: /
• Density: 1.397g/cm³
• Vapor Pressure: 3.74E-09mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Dichloromethane (Slightly, Heated), Methanol (Slightly)
• PKA: 3.43±0.10(Predicted)
• CAS DataBase Reference: (4-CHLORO-BENZOYLAMINO)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (4-CHLORO-BENZOYLAMINO)-ACETIC ACID(13450-77-6)
• EPA Substance Registry System: (4-CHLORO-BENZOYLAMINO)-ACETIC ACID(13450-77-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 13450-77-6(Hazardous Substances Data)

Usage

Uses

4-Chlorohippuric Acid is a derivative of Hippuric Acid (H356700) and is the major metabolite in human urine.

InChI:InChI=1/C9H8ClNO3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5H2,(H,11,14)(H,12,13)/p-1

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 56-40-6 glycine 
• 39735-52-9 N-(4-chloro)benzoyl glycine methyl ester 
• 59893-99-1 N-(p-chlorobenzoyl)-glycine methyl ester 
• 74-11-3 para-chlorobenzoic acid 
• 6000-43-7 2-aminoethanoic acid hydrochloride 
• 22887-53-2 2-(4-Chlorphenyl)-4,5-dihydro-1,3-oxazol-5-on 

Downstream Products

• 353280-77-0 2-(4-chloro-phenyl)-4-ethoxymethylene-4H-oxazol-5-one 
• 40547-10-2 2-(4-chloro-phenyl)-4-(3-nitro-benzylidene)-4H-oxazol-5-one 
• 75152-15-7 (4-Chloro-benzoylamino)-acetic acid 4-nitro-phenyl ester 
• 102674-43-1 methyl 4-chlorobenzoylglycyl-2-methylalaninate 
• 90448-14-9 2-(4-Chlorophenyl)-4-(4-difluoromethylsulfonylbenzylidene)oxazol-5-one 
• 94670-39-0 4-chloro-N-formylbenzamide 
• 103369-09-1 N-(acetoxymethyl)-4-chloro-benzamide 
• 56-40-6 glycine 
• 74-11-3 para-chlorobenzoic acid 
• 68661-24-5 1-(p-Chlorbenzoyl)-4-hydroxy-3-pyrrolin-2-on 
• 425380-45-6 (Z)-2-(p-chlorobenzoylamino)-N-(3'-dimethylaminopropyl)-3-(1-naphthyl)-2-propenamide 
• 80353-50-0 N-<2-(3,4-Dimethylphenyl)-2-oxoethyl>-4-chlorobenzamide 
• 80353-51-1 N-<2-(2,5-Dimethylphenyl)-2-oxoethyl>-4-chlorobenzamide 
• 1281969-74-1 C₁₆H₈BrClFNO₂ 

Relevant articles and documents

Physiologic disposition and metabolic fate of indomethacin analogs. II. 1-(p-chlorobenzoyl)-5-dimethylamino-2-methylindole-3-acetic acid.

-

4-Sulfamoylphenylalkylamides as Inhibitors of Carbonic Anhydrases Expressed in Vibrio cholerae

A current issue of antimicrobial therapy is the resistance to treatment with worldwide consequences. Thus, the identification of innovative targets is an intriguing challenge in the drug and development process aimed at newer antimicrobial agents. The state-of-art of anticholera therapy might comprise the reduction of the expression of cholera toxin, which could be reached through the inhibition of carbonic anhydrases expressed in Vibrio cholerae (VchCAα, VchCAβ, and VchCAγ). Therefore, we focused our interest on the exploitation of sulfonamides as VchCA inhibitors. We planned to design and synthesize new benzenesulfonamides based on our knowledge of the VchCA catalytic site. The synthesized compounds were tested thus collecting useful SAR information. From our investigation, we identified new potent VchCA inhibitors, some of them displayed high affinity toward VchCAγ class, for which few inhibitors are currently reported in literature. The best interesting VchCAγ inhibitor (S)-N-(1-oxo-1-((4-sulfamoylbenzyl)amino)propan-2-yl)furan-2-carboxamide (40) resulted more active and selective inhibitor when compared with acetazolamide (AAZ) as well as previously reported VchCA inhibitors.

Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents

A series of new indole derivatives 1–18 was synthesized and tested for their cytotoxic activity on a panel of 60 tumor cell lines. Additionally, molecular docking was carried out to study their binding pattern and binding affinity in the VEGFR-2 active site using sorafenib as a reference VEGFR-2 inhibitor. Based on the molecular docking results, compounds 5a, 5b, 6, 7, 14b, 18b, and 18c were selected to be evaluated for their VEGFR-2 inhibitory activity. Compound 18b exhibited a broad-spectrum antiproliferative activity on 47 cell lines, with GI % ranging from 31 to 82.5%. Moreover, compound 18b was the most potent VEGFR-2 inhibitor with an IC50 value of 0.07 μM, which is more potent than that of sorafenib (0.09 μM). A molecular docking study attributed the promising activity of this series to their hydrophobic interaction with the VEGFR-2 binding site hydrophobic side chains and their hydrogen bonding interaction with the key amino acids Glu885 and/or Asp1046.